CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study [Phase 2]
Summary
A Phase 2 open-label extension study of Daxdilimab (HZN-7734) for systemic lupus erythematosus was terminated; results were posted on 2024-09-19.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19